Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Melanoma | 50 | 2023 | 5444 | 3.800 |
Why?
|
Gastrointestinal Microbiome | 12 | 2024 | 944 | 2.740 |
Why?
|
Immunotherapy | 20 | 2024 | 3480 | 1.330 |
Why?
|
Skin Neoplasms | 17 | 2023 | 4775 | 1.260 |
Why?
|
Neoplasms | 22 | 2024 | 15695 | 1.250 |
Why?
|
Neoplasms, Second Primary | 5 | 2023 | 1377 | 1.150 |
Why?
|
Diet | 2 | 2024 | 1476 | 0.930 |
Why?
|
Obesity | 8 | 2023 | 2992 | 0.850 |
Why?
|
Antineoplastic Agents, Immunological | 7 | 2020 | 1313 | 0.820 |
Why?
|
Body Mass Index | 5 | 2023 | 2293 | 0.770 |
Why?
|
Exercise | 3 | 2023 | 1215 | 0.740 |
Why?
|
Fecal Microbiota Transplantation | 2 | 2021 | 149 | 0.720 |
Why?
|
Colitis | 4 | 2024 | 338 | 0.650 |
Why?
|
Programmed Cell Death 1 Receptor | 7 | 2021 | 1069 | 0.580 |
Why?
|
Qigong | 1 | 2016 | 12 | 0.560 |
Why?
|
Tai Ji | 1 | 2016 | 15 | 0.560 |
Why?
|
Waiting Lists | 3 | 2017 | 269 | 0.530 |
Why?
|
Ipilimumab | 9 | 2023 | 749 | 0.510 |
Why?
|
Interleukin-2 | 1 | 2018 | 851 | 0.500 |
Why?
|
Molecular Targeted Therapy | 4 | 2022 | 2370 | 0.490 |
Why?
|
Sleep Wake Disorders | 3 | 2016 | 358 | 0.470 |
Why?
|
Fatigue | 4 | 2016 | 1267 | 0.470 |
Why?
|
Diarrhea | 3 | 2021 | 689 | 0.440 |
Why?
|
Humans | 81 | 2024 | 270404 | 0.440 |
Why?
|
Recombinant Proteins | 1 | 2018 | 2941 | 0.430 |
Why?
|
Antigens, Neoplasm | 1 | 2018 | 1558 | 0.400 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2023 | 16258 | 0.400 |
Why?
|
Quality of Life | 7 | 2024 | 4719 | 0.390 |
Why?
|
Prebiotics | 2 | 2023 | 35 | 0.390 |
Why?
|
Proto-Oncogene Proteins B-raf | 6 | 2023 | 1325 | 0.390 |
Why?
|
Neoplasm Proteins | 2 | 2018 | 3288 | 0.360 |
Why?
|
Acupuncture Therapy | 3 | 2015 | 93 | 0.330 |
Why?
|
CTLA-4 Antigen | 4 | 2023 | 665 | 0.320 |
Why?
|
Probiotics | 2 | 2021 | 231 | 0.300 |
Why?
|
Tumor Microenvironment | 7 | 2023 | 2980 | 0.290 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 3 | 2022 | 1007 | 0.280 |
Why?
|
Hot Flashes | 3 | 2015 | 37 | 0.280 |
Why?
|
Middle Aged | 29 | 2024 | 89413 | 0.270 |
Why?
|
MAP Kinase Signaling System | 3 | 2019 | 885 | 0.260 |
Why?
|
Infliximab | 2 | 2024 | 140 | 0.250 |
Why?
|
Androgen Receptor Antagonists | 2 | 2023 | 109 | 0.250 |
Why?
|
Cancer Survivors | 2 | 2024 | 723 | 0.240 |
Why?
|
Prostatic Neoplasms | 2 | 2023 | 5936 | 0.230 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2018 | 717 | 0.230 |
Why?
|
Male | 29 | 2024 | 127406 | 0.230 |
Why?
|
T-Lymphocytes | 4 | 2021 | 3955 | 0.230 |
Why?
|
Mitogen-Activated Protein Kinase 7 | 1 | 2023 | 83 | 0.220 |
Why?
|
Female | 34 | 2024 | 147053 | 0.220 |
Why?
|
Survivors | 3 | 2017 | 1030 | 0.210 |
Why?
|
L-Lactate Dehydrogenase | 2 | 2021 | 314 | 0.210 |
Why?
|
Oximes | 3 | 2020 | 180 | 0.210 |
Why?
|
Thinness | 1 | 2023 | 84 | 0.210 |
Why?
|
Treatment Outcome | 14 | 2023 | 34163 | 0.210 |
Why?
|
Animals | 16 | 2024 | 60938 | 0.200 |
Why?
|
Protein Kinase Inhibitors | 6 | 2022 | 4884 | 0.200 |
Why?
|
Pyrimidinones | 3 | 2020 | 320 | 0.200 |
Why?
|
Dermatitis | 1 | 2022 | 61 | 0.200 |
Why?
|
Dietary Fiber | 1 | 2021 | 124 | 0.190 |
Why?
|
Oxidative Phosphorylation | 2 | 2019 | 258 | 0.190 |
Why?
|
Leukocyte L1 Antigen Complex | 1 | 2021 | 17 | 0.190 |
Why?
|
Pyridones | 3 | 2020 | 366 | 0.190 |
Why?
|
Encephalitis | 1 | 2022 | 146 | 0.190 |
Why?
|
Glutaminase | 1 | 2020 | 49 | 0.190 |
Why?
|
Retrospective Studies | 13 | 2024 | 39440 | 0.180 |
Why?
|
Oncolytic Virotherapy | 1 | 2023 | 257 | 0.180 |
Why?
|
Feces | 2 | 2021 | 809 | 0.180 |
Why?
|
Biological Products | 1 | 2024 | 311 | 0.180 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 383 | 0.180 |
Why?
|
Lymphocyte Depletion | 1 | 2021 | 290 | 0.180 |
Why?
|
Receptors, Androgen | 2 | 2023 | 893 | 0.170 |
Why?
|
Risk Factors | 6 | 2023 | 18229 | 0.170 |
Why?
|
Aged | 17 | 2024 | 72800 | 0.170 |
Why?
|
Overweight | 1 | 2023 | 494 | 0.170 |
Why?
|
Adult | 18 | 2022 | 80581 | 0.160 |
Why?
|
Lumbar Vertebrae | 1 | 2020 | 250 | 0.160 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2020 | 2733 | 0.160 |
Why?
|
Skin Diseases | 1 | 2021 | 357 | 0.160 |
Why?
|
Autoimmune Diseases | 1 | 2022 | 418 | 0.160 |
Why?
|
Pharmaceutical Preparations | 1 | 2019 | 152 | 0.150 |
Why?
|
Risk Assessment | 4 | 2020 | 7162 | 0.150 |
Why?
|
Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 464 | 0.150 |
Why?
|
Imidazoles | 3 | 2020 | 1028 | 0.150 |
Why?
|
Rare Diseases | 1 | 2021 | 358 | 0.150 |
Why?
|
Protective Factors | 1 | 2018 | 109 | 0.150 |
Why?
|
Antibodies | 2 | 2023 | 842 | 0.150 |
Why?
|
Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2018 | 131 | 0.150 |
Why?
|
Neoplasm Staging | 7 | 2023 | 13879 | 0.150 |
Why?
|
Leptin | 1 | 2019 | 307 | 0.150 |
Why?
|
Microbiota | 1 | 2023 | 552 | 0.150 |
Why?
|
B7-H1 Antigen | 3 | 2020 | 1057 | 0.150 |
Why?
|
Neurofeedback | 1 | 2017 | 19 | 0.140 |
Why?
|
Interleukin-6 | 1 | 2021 | 1057 | 0.140 |
Why?
|
Hepatitis B, Chronic | 1 | 2018 | 142 | 0.140 |
Why?
|
Breast Neoplasms | 6 | 2024 | 16050 | 0.140 |
Why?
|
Biomarkers, Tumor | 6 | 2021 | 10623 | 0.140 |
Why?
|
Mice | 11 | 2023 | 35283 | 0.140 |
Why?
|
Inflammation | 2 | 2023 | 2567 | 0.140 |
Why?
|
Cross-Cultural Comparison | 1 | 2017 | 92 | 0.140 |
Why?
|
Immunomodulation | 1 | 2018 | 255 | 0.140 |
Why?
|
Gastrointestinal Diseases | 1 | 2021 | 596 | 0.140 |
Why?
|
Taxoids | 2 | 2017 | 994 | 0.140 |
Why?
|
Signal Transduction | 6 | 2023 | 12135 | 0.130 |
Why?
|
Xerostomia | 2 | 2014 | 201 | 0.130 |
Why?
|
Antineoplastic Agents | 5 | 2023 | 14501 | 0.130 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 522 | 0.130 |
Why?
|
Transplant Recipients | 1 | 2018 | 330 | 0.130 |
Why?
|
DNA Copy Number Variations | 1 | 2023 | 1533 | 0.130 |
Why?
|
Antibodies, Monoclonal, Humanized | 3 | 2021 | 3361 | 0.130 |
Why?
|
GTP Phosphohydrolases | 1 | 2018 | 339 | 0.130 |
Why?
|
Metformin | 1 | 2019 | 390 | 0.130 |
Why?
|
Nausea | 2 | 2014 | 535 | 0.130 |
Why?
|
Cancer Vaccines | 1 | 2021 | 727 | 0.130 |
Why?
|
Adjuvants, Immunologic | 1 | 2018 | 697 | 0.120 |
Why?
|
Lung Neoplasms | 3 | 2023 | 11816 | 0.120 |
Why?
|
Dendritic Cells | 1 | 2021 | 1117 | 0.120 |
Why?
|
Central Nervous System Neoplasms | 1 | 2020 | 547 | 0.120 |
Why?
|
Dacarbazine | 1 | 2016 | 488 | 0.120 |
Why?
|
Immunotherapy, Adoptive | 2 | 2022 | 1890 | 0.120 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2016 | 199 | 0.120 |
Why?
|
Estrogens | 1 | 2018 | 758 | 0.120 |
Why?
|
Arthralgia | 1 | 2014 | 97 | 0.120 |
Why?
|
Aged, 80 and over | 6 | 2021 | 30767 | 0.120 |
Why?
|
C-Reactive Protein | 1 | 2017 | 560 | 0.110 |
Why?
|
Age Factors | 2 | 2020 | 5490 | 0.110 |
Why?
|
Hepatitis C, Chronic | 1 | 2018 | 465 | 0.110 |
Why?
|
Energy Metabolism | 1 | 2019 | 1007 | 0.110 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2016 | 595 | 0.110 |
Why?
|
Sleep | 1 | 2016 | 430 | 0.110 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2017 | 398 | 0.110 |
Why?
|
Young Adult | 7 | 2021 | 22096 | 0.110 |
Why?
|
Breathing Exercises | 1 | 2013 | 21 | 0.110 |
Why?
|
Quantitative Trait, Heritable | 1 | 2013 | 118 | 0.110 |
Why?
|
Texas | 3 | 2024 | 6454 | 0.110 |
Why?
|
Carcinogenesis | 1 | 2019 | 1048 | 0.100 |
Why?
|
Muscle, Skeletal | 1 | 2020 | 1328 | 0.100 |
Why?
|
Antibodies, Monoclonal | 3 | 2022 | 4442 | 0.100 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2019 | 5292 | 0.100 |
Why?
|
Disease Models, Animal | 3 | 2019 | 7414 | 0.100 |
Why?
|
Neoadjuvant Therapy | 2 | 2022 | 5105 | 0.100 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2022 | 10254 | 0.100 |
Why?
|
Thrombocytopenia | 1 | 2017 | 872 | 0.100 |
Why?
|
Time Factors | 4 | 2021 | 13251 | 0.100 |
Why?
|
Prognosis | 8 | 2021 | 22228 | 0.090 |
Why?
|
Carcinoma, Renal Cell | 1 | 2023 | 2387 | 0.090 |
Why?
|
Receptors, Estrogen | 1 | 2018 | 2122 | 0.090 |
Why?
|
PTEN Phosphohydrolase | 1 | 2015 | 999 | 0.090 |
Why?
|
Electroacupuncture | 1 | 2010 | 35 | 0.090 |
Why?
|
Ileus | 1 | 2010 | 31 | 0.090 |
Why?
|
Kidney Neoplasms | 1 | 2023 | 3097 | 0.080 |
Why?
|
Mutation | 3 | 2019 | 15577 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 4 | 2021 | 6265 | 0.080 |
Why?
|
Colectomy | 1 | 2010 | 290 | 0.080 |
Why?
|
Confidence Intervals | 2 | 2021 | 769 | 0.080 |
Why?
|
Polymorphism, Genetic | 1 | 2013 | 1470 | 0.070 |
Why?
|
Survival Analysis | 4 | 2022 | 9320 | 0.070 |
Why?
|
Disease-Free Survival | 4 | 2022 | 10092 | 0.070 |
Why?
|
Adolescent | 5 | 2021 | 32250 | 0.070 |
Why?
|
Phosphorylation | 3 | 2023 | 4885 | 0.070 |
Why?
|
Membrane Proteins | 1 | 2018 | 2914 | 0.070 |
Why?
|
Pain Management | 1 | 2013 | 703 | 0.070 |
Why?
|
Depression | 1 | 2017 | 1766 | 0.070 |
Why?
|
Cell Line, Tumor | 5 | 2021 | 14849 | 0.070 |
Why?
|
HIV Infections | 1 | 2018 | 2216 | 0.070 |
Why?
|
Mice, Inbred C57BL | 3 | 2021 | 7154 | 0.060 |
Why?
|
Incidence | 3 | 2021 | 5887 | 0.060 |
Why?
|
Genome, Human | 1 | 2013 | 1896 | 0.060 |
Why?
|
United States | 5 | 2024 | 16302 | 0.060 |
Why?
|
Biomarkers | 3 | 2021 | 5171 | 0.060 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 3620 | 0.060 |
Why?
|
Pandemics | 2 | 2024 | 1625 | 0.060 |
Why?
|
Antimetabolites | 1 | 2024 | 72 | 0.060 |
Why?
|
New York | 1 | 2023 | 106 | 0.060 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2023 | 1657 | 0.060 |
Why?
|
Cohort Studies | 3 | 2021 | 9476 | 0.060 |
Why?
|
DNA Methylation | 1 | 2013 | 2733 | 0.050 |
Why?
|
Neurosecretory Systems | 1 | 2023 | 64 | 0.050 |
Why?
|
Mucous Membrane | 1 | 2023 | 276 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 5465 | 0.050 |
Why?
|
Steroids | 1 | 2024 | 355 | 0.050 |
Why?
|
Fatty Acids, Volatile | 1 | 2021 | 52 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2019 | 4995 | 0.050 |
Why?
|
Colonic Neoplasms | 1 | 2010 | 1429 | 0.050 |
Why?
|
Disease Progression | 2 | 2023 | 6888 | 0.050 |
Why?
|
MART-1 Antigen | 1 | 2021 | 111 | 0.050 |
Why?
|
Goals | 1 | 2022 | 193 | 0.050 |
Why?
|
Italy | 1 | 2021 | 245 | 0.050 |
Why?
|
Response Evaluation Criteria in Solid Tumors | 1 | 2021 | 161 | 0.050 |
Why?
|
Combined Modality Therapy | 2 | 2023 | 9002 | 0.050 |
Why?
|
Multivariate Analysis | 2 | 2020 | 4383 | 0.050 |
Why?
|
Databases, Nucleic Acid | 1 | 2020 | 117 | 0.040 |
Why?
|
Interleukin-1beta | 1 | 2021 | 304 | 0.040 |
Why?
|
Positron-Emission Tomography | 2 | 2019 | 2210 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2019 | 3930 | 0.040 |
Why?
|
Australia | 1 | 2020 | 229 | 0.040 |
Why?
|
Melanoma, Experimental | 1 | 2021 | 377 | 0.040 |
Why?
|
Metabolic Flux Analysis | 1 | 2019 | 27 | 0.040 |
Why?
|
Observational Studies as Topic | 1 | 2020 | 155 | 0.040 |
Why?
|
Cell- and Tissue-Based Therapy | 1 | 2022 | 387 | 0.040 |
Why?
|
Oxadiazoles | 1 | 2019 | 60 | 0.040 |
Why?
|
Propensity Score | 1 | 2022 | 784 | 0.040 |
Why?
|
Meta-Analysis as Topic | 1 | 2020 | 282 | 0.040 |
Why?
|
Cell Count | 1 | 2020 | 512 | 0.040 |
Why?
|
Adrenal Cortex Hormones | 1 | 2022 | 558 | 0.040 |
Why?
|
Phenotype | 2 | 2023 | 6395 | 0.040 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 608 | 0.040 |
Why?
|
Oncogene Protein v-akt | 1 | 2019 | 102 | 0.040 |
Why?
|
Escherichia coli Infections | 1 | 2021 | 257 | 0.040 |
Why?
|
Tissue Array Analysis | 1 | 2020 | 764 | 0.040 |
Why?
|
Medicare | 1 | 2024 | 924 | 0.040 |
Why?
|
Prospective Studies | 3 | 2023 | 13269 | 0.040 |
Why?
|
History, 21st Century | 1 | 2020 | 450 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2020 | 509 | 0.040 |
Why?
|
Organ Size | 1 | 2020 | 732 | 0.040 |
Why?
|
Immunologic Factors | 1 | 2022 | 667 | 0.040 |
Why?
|
Evidence-Based Medicine | 2 | 2014 | 1130 | 0.040 |
Why?
|
Survival Rate | 2 | 2022 | 12428 | 0.040 |
Why?
|
Mutant Proteins | 1 | 2019 | 236 | 0.040 |
Why?
|
Uveal Neoplasms | 1 | 2020 | 188 | 0.040 |
Why?
|
Clostridium Infections | 1 | 2021 | 256 | 0.040 |
Why?
|
Virus Diseases | 1 | 2021 | 400 | 0.040 |
Why?
|
Gene Expression Profiling | 2 | 2020 | 5239 | 0.040 |
Why?
|
Intensive Care Units | 1 | 2022 | 747 | 0.040 |
Why?
|
Immunohistochemistry | 2 | 2020 | 7702 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2018 | 131 | 0.040 |
Why?
|
Inpatients | 1 | 2022 | 701 | 0.040 |
Why?
|
Heterografts | 1 | 2019 | 749 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2018 | 203 | 0.040 |
Why?
|
Mohs Surgery | 1 | 2018 | 102 | 0.040 |
Why?
|
Drug Therapy, Combination | 1 | 2022 | 2344 | 0.040 |
Why?
|
Platinum Compounds | 1 | 2017 | 129 | 0.040 |
Why?
|
Ribosomal Protein S6 | 1 | 2016 | 47 | 0.040 |
Why?
|
Hospital Mortality | 1 | 2022 | 1405 | 0.030 |
Why?
|
Proteomics | 1 | 2023 | 1422 | 0.030 |
Why?
|
Metabolome | 1 | 2019 | 350 | 0.030 |
Why?
|
CD8 Antigens | 1 | 2016 | 173 | 0.030 |
Why?
|
Standard of Care | 1 | 2018 | 267 | 0.030 |
Why?
|
Macrophages | 1 | 2022 | 1372 | 0.030 |
Why?
|
Endothelial Cells | 1 | 2022 | 1076 | 0.030 |
Why?
|
Mutation Rate | 1 | 2016 | 230 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 553 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2016 | 268 | 0.030 |
Why?
|
Length of Stay | 1 | 2022 | 2025 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2019 | 688 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2016 | 286 | 0.030 |
Why?
|
Protein Kinases | 1 | 2019 | 888 | 0.030 |
Why?
|
China | 1 | 2016 | 626 | 0.030 |
Why?
|
Remission Induction | 1 | 2021 | 3621 | 0.030 |
Why?
|
Aging | 1 | 2023 | 1578 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2018 | 688 | 0.030 |
Why?
|
Up-Regulation | 1 | 2020 | 2480 | 0.030 |
Why?
|
Organoplatinum Compounds | 1 | 2017 | 706 | 0.030 |
Why?
|
Graft Rejection | 1 | 2018 | 840 | 0.030 |
Why?
|
Morpholines | 1 | 2015 | 293 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2024 | 4527 | 0.030 |
Why?
|
Aminopyridines | 1 | 2015 | 219 | 0.030 |
Why?
|
Piperidines | 1 | 2019 | 1067 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2023 | 6241 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2016 | 656 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2019 | 9064 | 0.030 |
Why?
|
Intestinal Pseudo-Obstruction | 1 | 2013 | 39 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2018 | 905 | 0.030 |
Why?
|
Epistasis, Genetic | 1 | 2013 | 117 | 0.030 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2019 | 1559 | 0.030 |
Why?
|
Cytosine | 1 | 2013 | 149 | 0.030 |
Why?
|
Mitochondria | 1 | 2019 | 1307 | 0.030 |
Why?
|
Gene-Environment Interaction | 1 | 2013 | 167 | 0.030 |
Why?
|
Drug Synergism | 1 | 2015 | 1336 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2019 | 1706 | 0.030 |
Why?
|
Rituximab | 1 | 2017 | 1551 | 0.020 |
Why?
|
Mood Disorders | 1 | 2013 | 172 | 0.020 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2017 | 620 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2019 | 5509 | 0.020 |
Why?
|
Quantitative Trait Loci | 1 | 2013 | 384 | 0.020 |
Why?
|
Hydrocortisone | 1 | 2013 | 389 | 0.020 |
Why?
|
Mice, Nude | 1 | 2019 | 4343 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2020 | 5113 | 0.020 |
Why?
|
Genomics | 1 | 2022 | 2818 | 0.020 |
Why?
|
CpG Islands | 1 | 2013 | 654 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2016 | 2311 | 0.020 |
Why?
|
Tumor Burden | 1 | 2016 | 2018 | 0.020 |
Why?
|
Observer Variation | 1 | 2013 | 708 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2018 | 4228 | 0.020 |
Why?
|
Pilot Projects | 1 | 2017 | 2857 | 0.020 |
Why?
|
Defecation | 1 | 2010 | 59 | 0.020 |
Why?
|
Models, Statistical | 1 | 2016 | 1205 | 0.020 |
Why?
|
Genital Neoplasms, Female | 1 | 2017 | 775 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2018 | 3960 | 0.020 |
Why?
|
Postoperative Nausea and Vomiting | 1 | 2010 | 50 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2016 | 1457 | 0.020 |
Why?
|
Paclitaxel | 1 | 2017 | 2055 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2018 | 4052 | 0.020 |
Why?
|
Gastrointestinal Motility | 1 | 2010 | 94 | 0.020 |
Why?
|
Models, Biological | 1 | 2018 | 3254 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2021 | 3089 | 0.020 |
Why?
|
Patient Compliance | 1 | 2013 | 685 | 0.020 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2010 | 135 | 0.020 |
Why?
|
Treatment Failure | 1 | 2010 | 1431 | 0.020 |
Why?
|
Recovery of Function | 1 | 2010 | 723 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2013 | 1431 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2016 | 6192 | 0.020 |
Why?
|
Anxiety | 1 | 2013 | 1240 | 0.020 |
Why?
|
Radiotherapy | 1 | 2013 | 1852 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2020 | 15182 | 0.020 |
Why?
|
Surveys and Questionnaires | 1 | 2017 | 5913 | 0.010 |
Why?
|
Pain | 1 | 2013 | 1693 | 0.010 |
Why?
|
Pain, Postoperative | 1 | 2010 | 641 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2020 | 7732 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2018 | 5817 | 0.010 |
Why?
|
Child | 1 | 2016 | 30092 | 0.010 |
Why?
|